Check out our comprehensive educational activities here

What is standard of care for patients unfit for intensive induction chemotherapy, and what is under investigation?

Dr. Daver discusses the best options, both in current standard of care as well as under investigation, for treating patients unfit for intensive chemotherapy (generally patients above the age of 65).

Published on May 9, 2018 in Treatment

Therapy-related AML: Its relationship to de novo AML and how it impacts prognosis and treatment

Dr. Lancet explains what we know - and don't know - about therapy-related AML: its causes, features, treatment options, and prognosis.

Published on February 28, 2018 in Treatment

Approaching difficult-to-treat patients with relapsed FLT3 ITD AML

Dr. Pratz discusses how he manages patients with the historically difficult-to-treat relapsed FLT3 ITD acute myeloid leukemia.

Published on January 30, 2018 in Treatment

Using CPX-351 in the current treatment paradigm for AML

Dr. Lancet provides a brief overview on where CPX-351 fits into the current treatment paradigm for AML, particularly for patients with high-risk AML.

Published on January 18, 2018 in Treatment

FLT3 Inhibitors in AML: A Closer Look at the Changing Landscape

In this interview, Dr. Richard Stone provides his expert overview on trials involving FLT3 inhibitors that may impact future treatment best practices.

Published on January 15, 2018 in Treatment in Clinical Trials

Novel Therapies in AML

Dr. Lancet discusses the many new therapeutic advances seeking to have an impact on fit, elderly, and relapsed patients, as well as patients with specific targets. Listen to the exciting developments here.

Published on December 15, 2017 in Treatment

What is the future direction of the management of elderly patients with acute myeloid leukemia?

Watch Dr. Nazha discuss the future management of older patients with AML, including combining molecular targeted therapies with chemotherapy and other treatment approaches.

Published on November 29, 2017 in Treatment

Epigenetic Modifiers in AML: A Closer Look at Enasidenib, Ivosidenib, Pracinostat, Vorinostat, Pinometostat, and LDS1 Inhibitors

In this interview, AML thought-leader Dr. Eytan Stein details recent and ongoing clinical trials studying a variety of epigenetic modifiers.

Published on November 28, 2017 in Treatment in Clinical Trials

What is the definition of elderly in AML, and is there an age at which we decide not to treat?

Join Dr. Nazha as he defines elderly AML, discusses whether or not age should be a factor in deciding whether to treat a patient, and describes recommended treatments for patients of varying ages.

Published on October 9, 2017 in Treatment

CPX-351 and Vosaroxin: Developments in Chemotherapy for AML

In this interview, AML thought-leaders Dr. Jorge Cortes and Dr. Farhad Ravandi provide insight on recent and ongoing clinical trials studying CPX-351 and vosaroxin.

Published on September 29, 2017 in Treatment in Clinical Trials